Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs
LONDON (Reuters) - Shire ditched its revenue target of $20 billion by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance.
from Reuters: Health News http://reut.rs/2Ffjpa8
http://bit.ly/2zwRqiM